Company profile · Biotech & medical
EirGenix
台康生技股份有限公司 · 6589
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
EirGenix researches and develops biosimilars and new drugs, and provides biopharmaceutical contract development and manufacturing services.[1]
The company employs a dual-track approach of biopharmaceutical CDMO and product development, utilizing mammalian cell development and microbial strain fermentation development systems.[2]
Its core platform technologies include cell line development, process development and scale-up, analytical method development and validation, product characterization, cGMP production, and CMC documents.[2]
The mammalian cell culture cGMP facility utilizes single-use bioreactors ranging from 50L to 2,000L.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$272m | +287.9% | +131.5% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$79m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | EirGenix Inc. |
|---|---|
| Chinese name | 台康生技股份有限公司 |
| Stock code | 6589 (TWSE) |
| Industry | Biotech & medical |
| Founded | 21 Dec 2012 |
| Listed | 21 Jul 2025 |
| Paid-in capital | NT$3.0bn |
| Chairman | 劉理成 |
| President | 劉理成 |
| Headquarters | No.101, Lane 169, Kangning St., Xizhi Dist. New Taipei City 22180, Taiwan (R.O.C.) |
| Website | http://www.eirgenix.com |
| Official business description | 生物相似藥及新藥研發、生技藥品委託開發暨生產服務(CDMO) |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 台康生技股份有限公司 · mops · retrieved 04 Nov 2026
- Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list